Autologous Blood Immunization Method for Reduced Antigen Doses
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional immunization methods are inefficient, costly, and logistically challenging due to the need for multiple doses, complex schedules, and reliance on healthcare workers, with limitations in vaccine availability and safety concerns, especially in remote areas, and they often require large volumes and cold chain maintenance.
Innovation Solution
A method involving exposing a blood sample to immunogenic antigens or therapeutic agents and incubating it under specific conditions before reintroducing it into the individual, allowing for polyvalent simultaneous immunizations and treatment with reduced antigen or treatment agent quantities and doses, using routes like intravenous, intramuscular, or oral administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional vaccination methods are used, then immune protection is achieved, but multiple doses and complex schedules are required
Solution Approach 1:
The patent applies preliminary action by pre-exposing blood cells to antigens in vitro before reintroduction into the patient. This pre-processing of immune cells allows them to be primed with antigen exposure outside the body, eliminating the need for multiple sequential doses and complex scheduling. The blood draw, antigen exposure, and reinjection constitute a single preliminary action that achieves what conventional methods require multiple actions to accomplish.
2Reliability
If conventional vaccination methods are used, then immune response is stimulated, but large volumes and doses of vaccine are needed
Solution Approach 1:
The patent extracts immune cells (white blood cells) from the patient's blood, processes them externally with antigen exposure, and then returns them. This extraction allows the antigen to be presented directly to immune cells in a controlled in vitro environment, eliminating the need to inject large volumes of vaccine into tissue hoping some reaches immunocytes. The antigen is delivered precisely where needed - directly to the extracted immune cells - minimizing the total quantity required.
3Reliability
If conventional vaccination methods are used, then disease protection is achieved, but cold chain maintenance is required
Solution Approach 1:
The patent introduces an intermediary processing step where blood cells are exposed to antigens in a controlled laboratory setting before reinjection. This intermediary in vitro exposure acts as a mediator that decouples the antigen delivery from cold chain requirements. The antigen can be processed at controlled temperatures in the lab, and the resulting antigen-exposed blood cells can be stored and transported without stringent temperature control, as the immune cells have already been primed with the antigen exposure.
4Reliability
If conventional vaccination methods are used, then immunization is achieved, but multiple clinic visits are required
Solution Approach 1:
The patent merges multiple vaccination functions into a single integrated procedure. The blood draw, antigen exposure, and reinjection are combined into one clinic visit, replacing the multiple separate vaccination appointments required by conventional methods. This merging of steps eliminates the need for patients to return for follow-up doses, as the entire immunization process is accomplished in a single consolidated action.
5Reliability
If conventional vaccination methods are used, then protective immunity is generated, but interference between antigens occurs in polyvalent vaccines
Solution Approach 1:
The patent applies local quality by exposing different blood cell samples to different antigens separately in vitro, then combining the treated samples. Rather than mixing multiple antigens together in a single polyvalent formulation (which causes interference), each antigen is processed with its corresponding blood cell sample in a dedicated local environment. This localized processing of each antigen-cell interaction prevents cross-interference while maintaining the protective immunity benefits of multiple antigens.
Data Source
AI summary
A method immunizing an individual that minimizes the amount of antigen or attenuated organism needed and the number of doses and clinic visits required, while making possible polyvalent simultaneous immunizations. The method comprises the steps of obtaining a sample of blood. Exposing at least a portion of this sample to at least one immunogenic antigen, attenuant or other immunogen. Incubating the exposed sample under specified optimal conditions and introducing this exposed sample into the individual to effect immunization thereof. The method of the invention also provides a method of delivery of materials, other than antigens, throughout an individual's body such as therapeutic drugs, virus vectors, genes, DNA, RNA, isotopes, and other therapeutic substances. A method for the delivery of treatment material to an individual is also provided by this method.